USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CRINETICS PHARMACEUTICALS, INC.
Address:
6197 Cornerstone Ct, Suite111
SAN DIEGO, CA 92121-4718
Phone:
N/A
URL:
N/A
EIN:
126374411
DUNS:
828902515
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,040,340.00 4
SBIR Phase II $2,162,550.00 1

Award List:

Biosensors of GPCR Activation and Inhibition for Drug Discovery

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$237,895.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Measurements of the affinity, potency and efficacy of ligands to G protein-coupled receptors (GPCRs) are fundamental to pharmacology and drug discovery. Cellular functional assays measuring the production of GPCR second messengers such as cAMP and inositol… More

Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$282,070.00
Agency:
HHS
Principal Investigator:
Richard S. Struthers – 858-450-6464
Abstract:
DESCRIPTION (provided by applicant): Analogs of the neuropeptide somatostatin are important therapeutics for the treatment of hormone secreting tumors with annual sales in excess of 1.3B. However, currently available peptide depots are only effective in approximately half the patients with growth… More

Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$296,283.00
Agency:
HHS
Principal Investigator:
Stephen F. Betz – 858-450-6464
Abstract:
DESCRIPTION (provided by applicant): During the past decade, the discovery of kisspeptin peptides and their cognate receptor KISS1R (aka GPR54) has expanded our mechanistic understanding of the hypthothalamic-pituitary-gonadal (HPG) axis. The kisspeptin system has been shown to be an integrator of… More

Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$2,162,550.00
Agency:
HHS
Principal Investigator:
Richard S. Struthers – (858) 450-6464
Abstract:
DESCRIPTION (provided by applicant): Neuropeptide somatostatin analogs are important therapeutics for the treatment of hormone secreting tumors with annual sales of ~ 1.7B. However, the currently available peptide depots are effective in only half the patients with growth hormone secreting tumors,… More

Peripheral administration of nonpeptide somatostatin agonists for ophthalmic dise

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$224,092.00
Agency:
HHS
Principal Investigator:
Stephen F. Betz – 858-450-6464
Abstract:
Project Summary With an increasing older population, including the generational aging of the baby boomers , age-related eye diseases are common and becoming more prevalent. Currently, it is estimated that 11 million Americans suffer from age-related macular degeneration (AMD) - a number that is… More